Literature DB >> 19467705

Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.

A Hartman1, R H N van Schaik, I P van der Heiden, M J C Broekhuis, M Meier, M L den Boer, R Pieters.   

Abstract

INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.
METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.
RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.
CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467705     DOI: 10.1016/j.leukres.2009.04.027

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  Inherited genetic variation in childhood acute lymphoblastic leukemia.

Authors:  Takaya Moriyama; Mary V Relling; Jun J Yang
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 2.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 3.  Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Authors:  Erika Mora; Ellen M Lavoie Smith; Clare Donohoe; Daniel L Hertz
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

Review 4.  Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Authors:  Lin Mei; Evelena P Ontiveros; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2015-01-10       Impact factor: 8.250

5.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

6.  CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.

Authors:  Jodi L Skiles; ChienWei Chiang; Claire H Li; Steve Martin; Ellen L Smith; Gilbert Olbara; David R Jones; Terry A Vik; Saskia Mostert; Floor Abbink; Gertjan J Kaspers; Lang Li; Festus Njuguna; Tammy J Sajdyk; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.167

7.  Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Authors:  Francesco Ceppi; Chloé Langlois-Pelletier; Vincent Gagné; Julie Rousseau; Claire Ciolino; Samanta De Lorenzo; Kojok M Kevin; Diana Cijov; Stephen E Sallan; Lewis B Silverman; Donna Neuberg; Jeffery L Kutok; Daniel Sinnett; Caroline Laverdière; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

8.  Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Authors:  Guillermo Gervasini; Jose M Vagace
Journal:  Front Genet       Date:  2012-11-22       Impact factor: 4.599

Review 9.  Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.

Authors:  Sonja Pavlovic; Nikola Kotur; Biljana Stankovic; Branka Zukic; Vladimir Gasic; Lidija Dokmanovic
Journal:  Genes (Basel)       Date:  2019-03-01       Impact factor: 4.096

Review 10.  Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor.

Authors:  Qing-Yan Yang; Ya-Hui Hu; Hong-Li Guo; Ying Xia; Yong Zhang; Wei-Rong Fang; Yun-Man Li; Jing Xu; Feng Chen; Yong-Ren Wang; Teng-Fei Wang
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.